A Phase 2 interventional study of activated recombinant human factor VII and placebo in Acquired Bleeding Disorder and Dengue Haemorrhagic Fever, sponsored by Novo Nordisk A/S. Completed at 9 sites in 3 countries. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2017-01-11.
Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Dengue with a site in Thailand — 6 open to participants now, 8 under way, 4 of them phase 3. Dengue · Thailand.
Among the 30 studies in Dengue with a site in Thailand, this one is the 18th largest by enrollment of the 23 interventional ones that give a count, is the only one that started in 2001, is one of 6 in phase 2, and was the 9th registered.
283 studies on the registry are indexed under Dengue; 44 are open to participants now.
Browse Dengue studies →6 of the 30 studies in Dengue with a site in Thailand are open now. Recruiting first, the newest first:
Mahidol University · Sites in Thailand
Takeda · Sites in Thailand, Colombia
Ages 6 mo–20 mo · Healthy volunteers
Takeda · Sites in Thailand, Indonesia, Malaysia
Ages 6–12 · Healthy volunteers
Phramongkutklao College of Medicine and Hospital · Sites in Thailand
Ages 20+
Oxford University Clinical Research Unit, Vietnam · Sites in Thailand, Bangladesh, Brazil and 7 more countries
Ages 5+
A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →
Of the 27 Dengue studies recruiting now, 16 (59%) set no upper age limit and 11 (41%) stop at 75 or younger; 16 take children under 18; 9 take healthy volunteers.
This study: Up to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 12 · Phase 3 8
First in 2001; this study’s year is marked. 1 started in 2001.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 132 across 197 interventional studies indexed under Dengue.
Median enrollment 147 across the 23 interventional studies, 1,000 across the 7 observational. Of the 21 that completed or were terminated, 11 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 30 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Novo Nordisk A/S has 1 study filed under Dengue — fewer than ten, so there is no comparison to draw.
3 of the studies in Dengue with a site in Thailand that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06747130Phase 3Phramongkutklao College of Medicine and HospitalEfficacy of Montelukast in Preventing Transaminase Elevation in Adult Dengue Patients | 2027-01 |
| NCT06579755Phase 3TakedaA Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years) | 2027-04-14 |
| NCT07759596Mahidol UniversityBridging Economics and Public Trust: A Study of Dengue Vaccine Cost-effectiveness and Acceptance in Thais Visiting Hospital | 2026-12-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 30 studies in Dengue with a site in Thailand, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Asia. The aim of this is to investigate the efficacy and safety of activated recombinant human factor VII (rFVIIa) in achieving haemostasis in patients with Dengue haemorrhagic fever (DHF).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: activated recombinant human factor VII
Drug: placebo
100 mcg/kg body weight administered i.v. (into the vein) followed by standard haemostatic replacement therapy (SHRT) at the Investigator's discretion.
100 mcg/kg body weight administered i.v. (into the vein) followed by standard haemostatic replacement therapy (SHRT) at the Investigator's discretion.
Proportion of subjects with evidence of bleeding as assessed at 2 hours after first trial product administration
Proportion of subjects requiring standard haemostatic replacement therapy during 2 hours after first trial product administration
Proportion of subjects with effective haemostatic efficacy at 2 hours after first trial product administration
Coagulation related variables
Adverse events
The record gives a start of Jul 2001, a primary completion of Nov 2002 and a completion of Nov 2002. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Recombinant FVIIa